- What is Chronic immunotoxicity of immune checkpoint inhibitors?
- This anti-aging medicine has gone astray: Chronic inflammation leads to a decrease in NAD+
- FDA Approved Treatment Funded by Ice Bucket Challenge Donors
- Similar to HIV: Another deadly monkey virus may spread to humans
- 2022 Nobel Prize Winner Paper: The risk of severe COVID-19 is inherited from Neanderthals
- Breakthrough method ‘starves’ highly lethal cancer tumors and eradicates them
What is the role of breast cancer 21 gene detection?
What is the role of breast cancer 21 gene detection? Diagnosed with breast cancer, are you hesitating which treatment to choose? Breast cancer 21 gene detection by analyzing the tumor group of breast cancer patients.
Diagnosed with breast cancer, are you hesitating which treatment to choose? The 21-gene detection of breast cancer analyzes the expression levels of 21 genes in the tumor tissues of breast cancer patients, which can quantify the risk of recurrence and the benefit of chemotherapy, so as to avoid excessive treatment, effectively intervene and manage the disease process throughout the process, and improve survival benefits.
In July 2019, the Gene Decoding Research Center received a tumor tissue sample from Shanghai. The test item is: “Breast Cancer 21 Gene Detection”.
A 42-year-old female patient was admitted to the hospital due to a mass in her right breast and was diagnosed with breast invasive ductal carcinoma. Immunohistochemical results: ER (++), PR (-), Her-2 (-), E-cad (+), Ki-67 about 20%. Underwent lumpectomy surgery. A treatment plan needs to be developed after the operation. The doctor recommends a breast cancer 21 gene test to understand the risk of recurrence and whether to undergo chemotherapy. Submit the patient’s tumor tissue to genetic decoding for 21 genetic testing.
The staff tested and analyzed the expression levels of 21 genes in the patient’s tumor tissue, and calculated the recurrence score (RS) as 14.8 based on the gene expression results.
The subject’s recurrence score is 14.8, and the 10-year long-term recurrence risk is 9.5%, which is low risk. Sensitive to endocrine drugs, chemotherapy has little benefit, and chemotherapy is not recommended. Therefore, the endocrine drug tamoxifen can be considered for treatment.
“Breast Cancer 21 Gene Test” (Oncotype DX tumor gene test) analyzes the expression levels of 21 genes (16 breast cancer-related genes and 5 reference genes) in the tumor tissues of breast cancer patients to quantify the risk of recurrence and the benefit of chemotherapy . Help breast cancer patients understand whether they can benefit from chemotherapy in addition to receiving hormone therapy, that is, whether they need chemotherapy after surgery, and then help patients develop individualized treatment plans. It can also help doctors judge the risk of breast cancer recurrence, so as to avoid excessive treatment, effectively intervene and manage the disease process throughout the process, and improve survival benefits.
Breast cancer multi-gene detection project jointly recommended by international authoritative institutions!
National Comprehensive Cancer Network NCCN (2018): Recommend the use of breast cancer 21 gene detection for systemic adjuvant treatment options. It is suitable for patients with invasive breast cancer with negative lymph node, hormone receptor positive, HER2 negative, pT1, pT2 or pT3, and tumor tissue >12.5px.
American Society of Clinical Oncology ASCO (2016): For early invasive breast cancer with positive ER/PR, negative her2, and negative lymph nodes, clinicians can use the 21-gene score (RS) to guide the decision-making of systemic adjuvant chemotherapy.
St. Gallen International Breast Cancer Conference St.gallen (2017): Breast cancer 21 gene detection can predict the benefit of chemotherapy and endocrine therapy for patients with estrogen receptor-positive invasive breast cancer.
The significance of breast cancer 21 gene detection
Assist in the formulation of breast cancer treatment plans
Predict the patient’s risk of tumor recurrence and whether chemotherapy is needed.
Improve breast cancer patient management plan
Whether it is a low risk of recurrence or a high risk of recurrence, the results of the breast cancer 21 gene test can further assist in the development of an individualized tumor rehabilitation plan.
Avoid undertreatment or overtreatment
Chemotherapy is an effective means of treatment, but not all patients are suitable for chemotherapy. Sometimes unnecessary chemotherapy can even aggravate the patient’s condition.
- Newly diagnosed breast cancer patients with stage I or II, lymph node negative, estrogen receptor positive, and who will be treated with tamoxifen.
- Postmenopausal patients with invasive breast cancer with positive lymph nodes and estrogen receptor positive.
Advantages of breast cancer 21 gene detection project
01. Comprehensive testing content
Comprehensive detection and analysis of the expression levels of 21 genes including proliferation-related genes, invasion-related genes, hormone-related genes, HER2 related genes, and control genes.
02. Accurate test results
Strict testing and quality control links, quantify the test results as a recurrence score (RS), and accurately assess the risk of recurrence and the benefit of chemotherapy.
03. Professional Report Interpretation
Scientifically interpret the 10-year long-term recurrence risk and chemotherapy benefits of breast cancer patients, and assist clinicians in formulating individualized treatment plans for patients.
04. High clinical cost performance
Can fully cooperate with postoperative comprehensive treatment plan, detailed endocrine drug evaluation report.
- A. Fresh tissue: freshly operated tissue is 1 mung bean grain size;
- B paraffin tissue: 8-12 pieces of paraffin roll/paraffin white tablets.
- Testing cycle: 5-7 natural days (from the day the testing center receives qualified samples)
(source:internet, reference only)